Carregant...

Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial

Recurrence rate of hepatocellular carcinoma (HCC) is very high even after curative surgery, and no postoperative therapies have been definitively shown to prevent HCC recurrence. Sorafenib is proved to be effective for advanced HCC by two large randomized controlled trials in 2008 and 2009. Therefor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Hepatol
Autors principals: Zhong, Jian-Hong, Du, Xue-Ke, Xiang, Bang-De, Li, Le-Qun
Format: Artigo
Idioma:Inglês
Publicat: Baishideng Publishing Group Inc 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4990759/
https://ncbi.nlm.nih.gov/pubmed/27621761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v8.i23.957
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!